Using the Kaplan–Myer survival curves (Figure 4), adjuvant CT benefit seemed to be restricted to the group of patients with BRCA1-deficient tumors; there was a significant difference between the prognosis of patients affected by an hypermethylated tumor (p = 0.024) under adjuvant CT, without difference in patients that did not received adjuvant CT (p = 0.570). The gene discussed is BRCA1; the disease is neoplasm.